Universitas Islam Negeri Alauddin Makassar
[email protected] Portal Akademik Masuk
  1. Beranda
  2. Artikel
  3. Detail Artikel
Nature’s Blueprint: A New Era of Biomedical Innovation from Natural Sources

Nature’s Blueprint: A New Era of Biomedical Innovation from Natural Sources

11 Mei 2026 05:14 WITA Administrator Artikel

Nature’s Blueprint: A New Era of Biomedical Innovation from Natural Sources
By: Suriani, S.Si.,M.Si


Prologue: The Laboratory as a Garden

A quiet revolution is underway in the world's most advanced research laboratories. Beneath the cold blue glow of LED panels, surrounded by gleaming white surfaces and the hum of precision instruments, scientists are undertaking a practice that would have seemed almost contradictory a generation ago: they are reaching back into nature to build the future of medicine. Crab shells, seaweed, sweet wormwood, and the humble bacterium — once the domain of fishermen, herbalists, and microbiologists working in isolation — are now converging in a single, extraordinary narrative. This narrative constitutes the story of biomedicine derived from natural sources, and it is transforming the manner in which we understand healing, the human body, and the relationship between the living world and human technology.

The present essay traces that story across three remarkable frontiers: the 3D bioprinting of tissue scaffolds from marine-derived materials, the engineering of drug-delivery nanoparticles from crustacean shells, and the biosynthesis of life-saving pharmaceuticals inside engineered microorganisms. Collectively, these insights unveil a profound truth: that nature, far from being in opposition to high technology, emerges as its most sophisticated collaborator.

Part I: The Sea as Scaffold — Marine Collagen and Bacterial Cellulose in Bioprinting

The notion of printing human organs appears to be a product of science fiction, yet it is rapidly evolving into a scientific reality. The fundamental challenge of this revolution is, at first, an easily misunderstood one: namely, the question of which material should be used in the construction of living tissue. The answer to this question is increasingly derived from the ocean and from microbes — namely, marine-derived collagen and bacterial cellulose.

Collagen is the most abundant protein in the human body. It has been determined that this process constitutes the structural framework upon which the integumentary system, the musculoskeletal system, the nervous system, and the endocrine system are organized. For many years, the biomedical industry has relied on collagen extracted from bovine or porcine sources. However, there are potential risks associated with this, including immune reactions, disease transmission and ethical concerns [1].

Concerns have been raised. Marine collagen, derived from sources such as fish skin, scales, and jellyfish, presents a compelling alternative. It shares the same fundamental triple-helix protein structure as mammalian collagen but presents a cleaner immunogenic profile and a more sustainable sourcing pathway. The fish processing industries, which annually discard millions of tonnes of skin and scales, have the potential to become a valuable resource rather than a waste problem [2,3].

When combined with bacterial cellulose, a nanofibrous material produced by certain bacterial species such as Komagataeibacter xylinus, marine collagen yields a bioink of remarkable quality. Bacterial cellulose is distinguished from plant cellulose in that it is produced as a pure, ultrafine network of fibres, resulting in exceptional tensile strength and water-retention capacity [4,5]. This network functions as the physical backbone of the printed scaffold, while marine collagen provides the biochemical environment that cells recognise as home.

In a 3D bioprinter, the composite material is loaded into a cartridge alongside living cells, then extruded in precise, layer-by-layer formations to construct tissue geometry. The result of the experiment is a scaffold that has been engineered to mimic the extracellular matrix, i.e. the biological environment in which cells are found [6].

The implications of this phenomenon are profound. The shortage of donors is a significant constraint on the capacity of the organ transplantation system. The advent of bioprinted organs, cultivated from a patient's own cells on a natural scaffold, has the potential to eliminate the issue of organ rejection, reduce waiting times, and democratise access to life-saving procedures within the coming decades [7,8]. Marine life, which has evolved structural proteins under pressure, temperature, and saltwater for hundreds of millions of years, has unwittingly provided the blueprint for one of medicine's greatest ambitions [2,9].

Part II: From Shell to Salvation — Chitosan Nanoparticles and Targeted Drug Delivery

A perusal of the literature on the subject reveals that a common phenomenon is the presence of large accumulations of discarded crab and shrimp shells on coastal fishing wharfs. However, these discarded exoskeletons contain one of the most versatile biomaterials known to science: chitin. Following deacetylation, a chemical process that involves the removal of acetyl groups from the polymer chain, chitin is converted into a substance known as chitosan. This material has garnered significant attention in the field of pharmaceutical research, becoming a subject of extensive study [10].

Chitosan is notable for its biological properties. The substance under discussion has been found to be biocompatible, a designation that signifies the absence of any adverse bodily reaction to it. It is biodegradable, and upon decomposition, it releases amino sugars that are non-toxic to humans. The substance has been demonstrated to possess antimicrobial properties. It is crucial to note that the substance carries a positive electrical charge at physiological pH. This property gives it an extraordinary affinity for negatively charged cell and mucous membranes, enabling it to adhere, penetrate and release its contents with precision [11].

These properties render chitosan an almost ideal material for use in drug delivery nanoparticles. Nanoparticles are structures measured in nanometers – billionths of a meter – and thus small enough to travel through the bloodstream, navigate biological barriers, and interact with individual cells. The formation of chitosan nanoparticles that encapsulate a drug payload instigates a series of reactions. The nanoparticle's primary function is to protect the drug from degradation in the harsh environment of the bloodstream. The substance under discussion circulates through the body. If engineered with appropriate surface ligands — molecular tags that recognize specific proteins on target cells — it can bind selectively to cancer cells, infected tissues, or inflamed sites, releasing its payload precisely where it is needed [12].

The merits of this approach become evident when juxtaposed with conventional chemotherapy. Conventional cytotoxic pharmaceuticals are administered systemically, thus travelling through the entire body and indiscriminately attacking not only tumour cells, but also healthy tissue. The adverse effects of chemotherapy, including hair loss, nausea and immunosuppression, are a consequence of these drugs' inability to differentiate between cancerous and healthy cells. In contrast, the functionalization of Chitosan nanoparticles with antibodies or peptides that recognize antigens overexpressed on tumour surfaces enables the delivery of lethal concentrations of drugs directly to malignant tissue while sparing healthy cells [13].

Research published in the journal Carbohydrate Polymers has demonstrated the successful delivery of doxorubicin, a potent chemotherapy agent, to breast cancer cells by chitosan nanoparticles. This delivery method has been shown to result in significantly higher tumour accumulation and reduced systemic toxicity in comparison with conventional free drug administration [14]. Furthermore, studies have explored the use of chitosan systems for gene therapy, vaccine delivery, and the treatment of inflammatory bowel disease, where the mucoadhesive properties of chitosan allow prolonged contact with the intestinal mucosa [15].

These nanoparticles can be conceptualized as depicted in the most sophisticated scientific renderings: radiant blue carriers, luminescent in the obscurity of a digital bloodstream, navigating towards their targets with molecular quiet precision. The image is not merely an artistic licence; fluorescent chitosan nanoparticles are genuinely utilized in research settings, where they are labelled with imaging agents to track their journey through living tissue in real time. The transformation of the crab shell into a guided missile, and the conversion of the fishing industry's waste product into the raw material for precision oncology, exemplifies the potential for sustainable innovation in the context of environmental and health concerns [16].

Part III: The Engineered Yeast — Artemisinin and the Biosynthesis Revolution

The story of artemisinin is one of the most remarkable in modern medicine. For centuries, the Chinese herbalist community has utilised the plant Artemisia annua, commonly referred to as sweet wormwood, in the treatment of fever. The pharmacologist Tu Youyou isolated the active compound from the plant and demonstrated its extraordinary efficacy against malaria. Her discovery was to earn her the Nobel Prize in Physiology or Medicine in 2015, and artemisinin-based combination therapies are now the frontline treatment for Plasmodium falciparum malaria, the deadliest form of a disease that still kills hundreds of thousands of people annually [17].

For many years, the production of artemisinin was dependent on the cultivation of Artemisia annua, a process which was vulnerable to agricultural unpredictability, climate variation, and the economics of smallholder farming in the developing world. A drought in one season could cause prices of artemisinin to increase, thus rendering life-saving medication inaccessible to populations most in need. The central question guiding this research was whether it was possible to transplant the molecular machinery of Artemisia annua into a more controllable organism [18].

The molecular structure of artemisinin is a remarkable example of chemical complexity, featuring a sesquiterpene lactone with an unusual endoperoxide bridge, which is responsible for its antimalarial activity. This bridge reacts with iron within malaria parasites, generating toxic free radicals that destroy the pathogen from within. Artemisinin can be visualised as a holographic molecular model, with its structure being constituted by a three-dimensional sculpture of carbon rings and oxygen atoms. This intricacy is both beautiful and devastating in terms of its biological effect [19].

The success of artemisinin biosynthesis in yeast initiated a process that has since become a paradigm shift in the field. In recent developments, researchers are undertaking the engineering of microorganisms to produce opioids, cannabinoids, taxol (the cancer drug originally derived from Pacific yew trees), resveratrol, and an expanding array of natural products that were formerly constrained by the limitations of agriculture and extraction chemistry [20]. The discovery of these compounds occurred in natural environments, including plants, fungi, and marine organisms. Currently, there is a move towards democratizing their use through the application of metabolic engineering tools.

Epilogue: Nature and Technology as One

A unifying philosophy emerges when considering these three frontiers in isolation: namely, bioprinted scaffolds from marine proteins, chitosan nanoparticles from crustacean shells, and biosynthesized pharmaceuticals from engineered yeast. The future of biomedicine must be distinguished from a rejection of nature in favour of synthetic materials, as well as from a naive return to herbalism and folk remedy. This approach is characterised by a sophisticated and optimistic perspective, encompassing a profound examination of nature's solutions to biological challenges. Subsequent to this examination, human ingenuity is employed to translate, amplify, and deploy these solutions on a scale that surpasses what the natural world itself could achieve.

It is estimated that the ocean has invested a considerable amount of time, spanning 500 million years, in the refinement of structural proteins. Crustaceans have evolved exoskeletons that exhibit extraordinary biocompatibility. It is evident that plants have developed chemical arsenals against parasites and pathogens over the course of evolution. In each instance, the solution to the problem at hand was provided by nature itself. The role of modern biomedicine is to understand that solution, deconstruct it to its molecular logic, and rebuild it — in a bioprinter, a nanoparticle, or a fermentation vessel — in service of human health.

This endeavor is not merely an intellectual undertaking; it is a commitment to the pursuit of knowledge and understanding. The magnitude of these stakes is evident in the lives lost: in patients awaiting organs that are not available; in cancer patients subjected to toxic therapies that lack the capacity to differentiate between friend and foe; and in children succumbing to malaria in sub-Saharan Africa due to a lack of access to medication. The convergence of marine biology, polymer chemistry, synthetic biology, and nanotechnology is not merely theoretical; it is the most practical and urgent endeavor of our time.

The laboratory, it transpires, is a kind of garden. Within this ecosystem, the most sophisticated instruments of human civilization are cultivating seeds that were sown by nature long before the arrival of Homo sapiens.

Reference

1. Browne, S.; Zeugolis, D. I. Collagen?: Finding a Solution for the Source. TISSUE Eng. Part A 2013, 19, 36–39. https://doi.org/10.1089/ten.tea.2012.0721.
2. Coppola, D.; Oliviero, M.; Vitale, G. A.; Lauritano, C.; Ambra, I. D.; Iannace, S.; Pascale, D. De. Marine Collagen from Alternative and Sustainable Sources?: Extraction , Processing and Applications. Mar. Drugs 2020, 18 (214), 1–23.
3. Ahmed, R.; Haq, M.; Chun, B. Characterization of Marine Derived Collagen Extracted from the By-Products of Bigeye Tuna (Thunnus Obesus). Int. J. Biol. Macromol. 2019. https://doi.org/10.1016/j.ijbiomac.2019.05.213.
4. Swingler, S.; Gupta, A.; Gibson, H.; Kowalczuk, M.; Heaselgrave, W.; Radecka, I. Recent Advances and Applications of Bacterial Cellulose in Biomedicine. Polymers (Basel). 2021, 412 (13), 1–29.
5. Utoiu, E.; Manoiu, V. S.; Oprita, E. I.; Craciunescu, O. Bacterial Cellulose?: A Sustainable Source for Hydrogels and 3D-Printed Scaffolds for Tissue Engineering. Gels 2024, 387 (10), 1–20.
6. Nagaraja, K.; Dhokare, P.; Bhattachariyya, A.; Noh, I. Recent Advances in 3D Bioprinting of Polysaccharide-Based Bioinks for Fabrication of Bioengineered Tissues. Mol. Syst. Des. Eng. 2024, 9 (10), 977–999. https://doi.org/10.1039/d4me00001c.
7. Murphy, S. V; Atala, A. Review 3D Bioprinting of Tissues and Organs. Nat. Publ. Gr. 2014, 32 (8), 773–785. https://doi.org/10.1038/nbt.2958.
8. Vijayavenkataraman, S.; Yan, W.; Feng, W.; Wang, C.; Ying, J.; Fuh, H. 3D Bioprinting of Tissues and Organs for Regenerative Medicine ?. Adv. Drug Deliv. Rev. 2018, 132, 296–332. https://doi.org/10.1016/j.addr.2018.07.004.
9. Silva, T. H.; Moreira-Silva, J.; Marques, A. .; Domingues, A.; Bayon, Y.; Reis, R. L. Marine Origin Collagens and Its Potential Applications. Mar. Drugs 2014, 5881–5901. https://doi.org/10.3390/md12125881.
10. Kou, S.; Peters, L.; Mucalo, M. Chitosan: A Review of Sources and Preparation Methods. Int. J. Biol. Macromol. 2020. https://doi.org/10.1016/j.ijbiomac.2020.12.005.
11. Younes, I.; Rinaudo, M. Chitin and Chitosan Preparation from Marine Sources. Structure, Properties and Applications. Mar. Drugs 2015, 1133–1174. https://doi.org/10.3390/md13031133.
12. Masood, F. Polymeric Nanoparticles for Targeted Drug Delivery System for Cancer Therapy. Mater. Sci. Eng. C 2016, 60, 569–578. https://doi.org/10.1016/j.msec.2015.11.067.
13. Mitragotri, S.; Burke, P. A.; Langer, R. Overcoming the Challenges in Administering Biopharmaceuticals: Formulation and Delivery Strategies Samir. Nat. Rev. Drug Discov. 2015, 13 (9), 655–672. https://doi.org/10.1038/nrd4363.Overcoming.
14. Bhattarai, N.; Gunn, J.; Zhang, M. Chitosan-Based Hydrogels for Controlled , Localized Drug Delivery ?. Adv. Drug Deliv. Rev. 2010, 62 (1), 83–99. https://doi.org/10.1016/j.addr.2009.07.019.
15. Antoniou, V.; Mourelatou, E. A.; Galatou, E.; Avgoustakis, K.; Hatziantoniou, S. Gene Therapy with Chitosan Nanoparticles?: Modern Formulation Strategies for Enhancing Cancer Cell Transfection. Pharmaceutics 2024, 1–28.
16. Li, J.; Cai, C.; Li, J.; Li, J.; Li, J.; Sun, T.; Wang, L.; Wu, H.; Yu, G. Chitosan-Based Nanomaterials for Drug Delivery. Molecules 2018, 1–26. https://doi.org/10.3390/molecules23102661.
17. White, N. . Qinghaosu (Artemisinin): The Price of Success. Science (80-. ). 2008, 330. https://doi.org/10.1126/science.1155165.
18. Paddon, C. J.; Keasling, J. D. Gy Semi-Synthetic Artemisinin?: A Model for the Use of Synthetic Biology in Pharmaceutical Development. Nat. Rev. 2014, 12 (355–367). https://doi.org/10.1038/nrmicro3240.
19. Meshnick, S. R. Artemisinin?: Mechanisms of Action , Resistance and Toxicity. Int. J. Parasitol. 2002, 32, 1655–1660.
20. Galanie, S.; Thodey, K.; Trenchard, I. j; Interrante, M. F.; Smolke, C. D. Complete Biosynthesis of Opioids in Yeast. Science (80-. ). 2016, 349 (6252), 1095–1100. https://doi.org/10.1126/science.aac9373.Complete.